Future research in EGPA should be targeted at clarifying its pathophysiology and the therapies best suited to achieve optimal outcomes. The diagnostic landscape of eosinophilic granulomatosis with ...

Red blood cell antibody seroconversion in pregnancy was uncommon, with a rate of 0.26%. Clinically significant antibody seroconversion of red blood cells during pregnancy is rare, occurring in only ...

(Getty Images) The SPPB is a validated tool to predict morbidity and mortality, often among older adults. After adjusting for covariates, each 1-point increase in SPPB score was associated with a 13% ...

To treat my Chronic inflammatory demyelinating polyneuropathy (CIDP), I was given a 5-day induction dose of intravenous immunoglobulin (IVIG). The first dose went well, but the second day was awful, ...

The study revealed that the 2022 criteria demonstrated high sensitivity and specificity for EGPA, low sensitivity and high specificity for GPA, and high sensitivity and low specificity for MPA, with ...

The varied manifestations of IgG4-RD can make the diagnosis challenging, but prompt treatment can resolve symptoms and prevent recurrence. A new case has been reported of a patient with immunoglobulin ...

In NMOSD, satralizumab is believed to be more effective in preventing relapse of optic neuritis than of myelitis. Satralizumab was safe and effective at preventing relapses of optic neuritis in ...

Man with hand on his chest, seeing doctor Over time, the number of new ATTR-CM diagnoses with no heart failure symptoms progressively increased. Symptomatic heart failure developed in 50% of patients ...

Because acute chest syndrome in SCD can be life-threatening, it is important for physicians to recognize this disorder and initiate treatment accordingly. Acute chest syndrome (ACS) is one of the most ...

Efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo ®) precision therapy has been approved by China’s National Medical Products Administration (NMPA) to treat chronic inflammatory demyelinating ...

The authors observed no causal relationship between CIDP or Gillian Barre syndrome (GBS) and the presence of any of the 22 antibody immune responses. The presence of herpesvirus antibodies did not ...

The proportion of patients treated with rituximab as a first-line treatment having the most severe disease stage decreased over 5 years. The early treatment of patients with neuromyelitis optica ...